Blood plasma derivatives are medical products manufactured from blood plasma which contains important proteins necessary for blood clotting and maintaining normal blood pressure. Some key blood plasma derivatives include immunoglobulins, coagulation factors, albumin and hyperimmune globulins. These derivatives find wide applications in treatment of primary immunodeficiencies, hemophilia, hypogammaglobulinemia and other chronic diseases.

The global blood plasma derivatives market is estimated to be valued at US$ 44.33 Bn or Mn in 2023 and is expected to exhibit a CAGR of 13.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

The increasing prevalence of chronic diseases across the globe is one of the major drivers fueling the growth of the Global Blood Plasma Derivatives Market Size. As per estimates by the WHO, chronic diseases accounted for approximately 60% of total reported deaths in the world in 2001 and the proportion is expected to increase further in coming years. Growing geriatric population is also leading to rising cases of immunodeficiency disorders, hemophilia, hypogammaglobulinemia and other conditions requiring plasma derivative therapies. Additionally, ongoing technological advancements in plasma collection methods and fractionation processes are enabling increased yields of derivatives which is positively impacting the market growth. However, high costs associated with derivative therapies and stringent regulatory norms for plasmapheresis centers may hamper the market growth during the forecast period.

SWOT Analysis

Strength: The blood plasma derivatives market has significant growth opportunities due to rising plasma collection worldwide. Demand for plasma derivatives is increasing for use in treatment of hemophilia, primary immunodeficiency disorders. Growing geriatric population dealing with chronic diseases boosts the market. Regulatory bodies supporting plasma collection and manufacturing is positive for the industry.
Weakness: Stringent regulatory norms for plasma collection and manufacturing lead to increased cost of production. Risk of transfusion transmissible infections is a challenge. Lack of plasma collection centers and donors in developing regions hamper market growth.
Opportunity: Emerging economies offer growth prospects due to increasing healthcare investments. Growing patient awareness levels regarding benefits of plasma therapies present opportunities. Development of recombinant alternatives especially for coagulation factors will drive the growth. Scope for implementing advanced plasma thawing and viral inactivation methods.
Threats: Threat from substitutes like recombinant alternatives for coagulation factors can hamper the market. Decline in reimbursement rates affects the sales and profit margins. Rising competition among existing players impacts the market share.

Key Takeaways

The global blood plasma derivatives market is expected to witness high growth. Factors such as rising prevalence of hemophilia and other bleeding disorders, faster approval of new plasma products and increasing aging population are driving the market growth.

Regional analysis:

North America currently dominates the blood plasma derivatives market owing to established healthcare infrastructure, favorable reimbursement policies and presence of major market players in the region. Asia Pacific is expected to witness fastest growth during the forecast period supported by expansion of plasma collection centres, growing healthcare spending and rising patient awareness in the region.

Key players:
Key players operating in the blood plasma derivatives market are Thermo Fisher Scientific, Inc., Custom Biogenic Systems, Chart Biomedical Co. Ltd., Merck KGaA, Barber-Nichols Inc., Praxair Technology, Inc., Linde LLC, Planer PLC, Cryologic Pty. Ltd., Charter Medicals, Nikkiso Cryo Inc., Cryogenic Control, and Haimen United Laboratory Equipment Development Co., Ltd.

The global blood plasma derivatives market is expected to witness high growth driven by rising prevalence of bleeding disorders and faster new product approvals. North America currently dominates the market supported by developed healthcare infrastructure and favorable reimbursement policies. Asia Pacific presents lucrative opportunities for expansion owing to infrastructure developments, healthcare spending growth and patient awareness rise in the region. Key players are focused on expanding their presence through new product launches and capacity expansion primarily in emerging Asian markets.

Get More Insights On This Topic: https://www.trendingwebwire.com/blood-plasma-derivatives-market-analysis-growth-forecast-outlook-2023-2030/